Analysis of KIF15 and DLGAP5 i KO s. (A) Secondary screen CRISPR score of KIF15 and DLGAP5 iKOs in HeLa and K562 cells. (B) Representative Z-projected deconvolved immunofluorescence images of mitotic cells of control, KIF15, or DLGAP5 iKO HeLas treated with either nocodazole, paclitaxel, or STLC. Microtubules (DM1α), DNA (DAPI). Scale bar: 9 µm. (C) Percentage of cells with mitotic defects in control or KIF15 iKO, treated with nocodazole (noc), paclitaxel (pac), or STLC. n > 300 cells per condition, across three experimental replicates. (D) Percent of cells with mitotic defects after iKO of DLGAP5, treated with nocodazole, paclitaxel, or STLC. n > 300 cells per condition, across three experimental replicates. (E) Quantification of total spindle tubulin signal in control, KIF15, or DLGAP5 iKO HeLas. n = 71, 60, 96 across three experimental replicates. See Fig. S3 A for representative images. (F) Quantification of total EB1 signal in KIF15 iKO and DLGAP5 iKO HeLa cells. n = 71, 60, 96 across three experimental replicates. Statistical tests performed: Welch’s t test (ns = not significant, ****P = <0.0001). Blue lines indicate the median.